Medtronic Cardiovascular offers a breadth of technologies at the therapeutic, procedural and system level across cardiovascular diseases. Additionally, we offer a breadth of services to help customers address their unique challenges and support enhanced patient experience, increased capacity, and improved clinical outcomes.
Below you will find more information on:
We're transforming your ability to diagnose and treat even the most difficult-to-detect arrhythmias with a variety of Insertable Cardiac Monitors (ICMs). To learn more about our product portfolio, visit the site below:LEARN MORE ABOUT CARDIAC DIAGNOSTIC & MONITORING SYSTEMS
Atrial fibrillation, also known as AF, is an irregular heart rhythm that affects the upper chambers (atria) of the heart. In AF, the atria quiver instead of beating normally. AF can also lead to rapid heart rhythm, where the heart can beat as much as 300 times a minute or more in the atria and up to 150 times a minute or more in the lower chambers (ventricles).
Catheter ablation for AF is a technique employed to control heart rhythms that are caused by abnormal electrical signals traveling from the pulmonary veins to the atria. It’s a minimally invasive procedure that can be used when medication fails to control AF. During the procedure, catheters are used to terminate (ablate) these abnormal electrical signals and stop them from spreading and continuing to cause AF.
The catheters have electrodes that can sense intracardiac electrical signals when connected to the electrophysiology lab system. The resulting electrograms are used to determine the optimal placement of the ablation catheter. The ablation catheter delivers energy to create a discrete lesion of myocardial scar tissue which terminates the abnormal electrical signals.
Medtronic offers ablation catheters that use cryothermal energy to create lesions via the rapid removal of heat from cardiac cells.
With its proven safety and efficacy profile, the Arctic Front™ family of cryoballoons are approved in the U.S. to treat drug refractory, recurrent, symptomatic, paroxysmal, and persistent atrial fibrillation (episode duration less than 6 months).1 The cryoballoon, paired with the flexcath advance steerable sheath and achieve family of mapping catheters is used for AF physiological intervention that delivers a consistent, simple pulmonary vein isolation (PVI) ablation procedure with safe cryo technology. Over 650,000 patients worldwide have been treated with the cryoballoon.2SEE ARTIC FRONT
Peripheral Arterial Disease (PAD), which can also be referred to as peripheral vascular disease (PVD), is the narrowing or blockage of arteries in various critical regions of the body. When the disease presents in the lower limbs, blood flow is reduced and can cause damage to tissue in your lower limbs. PAD is a progressive disease ranging from mild to moderate Claudication to Critical Limb Ischemia (CLI) which can lead to amputation.
PAD is a progressive disease that can limit patients mobility, quality of life, and if not addressed can lead to amputation. Endovascular treatment options including balloon angioplasty, atherectomy, and stenting are minimally invasive therapies to treat blocked arteries without the need for open surgery.
Medtronic offers a suite of endovascular technology solutions that enable effective treatment of claudication including the HawkOne™ directional atherectomy system, the IN.PACT™ Admiral™ Drug Coated Balloon, and the Chocolate™ PTA balloon catheter.FIND OUT MORE
Critical Limb Ischemia (CLI) is a growing health concern that significantly impacts patient quality of life and ability to function. As the population ages, the disease will become more prevalent.
Medtronic's products can help you address this debilitating disease by relieving pain, improving function, and restoring hope for CLI patients.
Medtronic’s portfolio to treat CLI disease includes technologies to access, cross, and treat multilevel disease with confidence.LEARN ABOUT CLI
The IN.PACT AV Drug-Coated Balloon for AV fistula maintenance can slow the progression of fistula stenosis. A functioning fistula can eliminate the need for catheter-based dialysis, decreasing risk of infection and all-cause mortality.3
The IN.PACT AV DCB may enable dramatically fewer AV fistula reinterventions, which could keep patients out of the hospital longer for AV fistula maintenance.3 It can make a real impact – clinically, financially,4 and emotionally.DISCOVER IN.PACT
Combining proven Lean Sigma methodologies with extensive change management expertise, we work directly with your healthcare administration leaders and care teams to find solutions to the unique challenges at your site impacting operational efficiency, staff satisfaction and performance, and the patient experience.
We have successfully led more than 120 hospital and clinic engagements in a wide range of cardiovascular settings, including cardiac catheterization (cath) and electrophysiology (EP) labs, hybrid operating room (OR) settings, and outpatient clinics.
Healthcare optimization engagements are always customized to meet your specific goals. Whether it’s building a new program or refining an existing one, we’re here to help you expand patient access, improve the quality and cost-effectiveness of healthcare delivery, and ensure sustainable success.
The next generation McGRATH™ MAC video laryngoscope is an enhanced, more robust device, designed to be durable and used throughout the day. Add McGRATH™ to your ASC to make your first attempt your best.
Explore treatment options, learn about our therapy, find a physician, and access materials and resources here.
Patients can also sign up to receive monthly updates.
Learn more about Peripheral arterial disease, the signs and symptoms, and treatment options.
Patient Information Booklet – Understanding chronic kidney disease and the IN.PACT AV Drug-Coated Balloon for AV fistula maintenance:
In support of our products, we provide resources to assist with coding, coverage and reimbursement for our therapies.
Medical necessity will dictate site of service for each individual patient. Physicians should confirm inpatient or outpatient admission criteria before selecting site of service.
Packer DL, et al. Cryoballoon Ablation of Pulmonary Veins for Paroxysmal Atrial Fibrillation: First Results of the North American Arctic Front (STOP AF) Pivotal Trial. J Am Coll Cardiol. 2013 Apr 23; 61(14):1713-1723.
Medtronic data on file.
Lookstein RA, et al. Drug-Coated Balloons for Dysfunctional Dialysis Arteriovenous Fistulas. N Engl J Med 2020;383:733-42. DOI: 10.1056/NEJMoa1914617. Highlighted results reported at both 180 and 210 days.
Thamer M, Lee TC, Wasse H, et al. Medicare Costs Associated With Arteriovenous Fistulas Among US Hemodialysis Patients. Am J Kidney Dis. July 1, 2018;72(1):10-18.